

January 26, 2011

Press Release

[Mitsubishi Tanabe Pharma Corporation](#)

Notice Regarding Voluntary Recall of Three Drugs (Six Dosage Sizes)

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka, President and Representative Director: Michihiro Tsuchiya) announces that the Company decided to voluntarily recall, from today, certain lots of three drugs (six dosage sizes) that are manufactured and sold by the Company. These drugs are Liple 5 µg and 10 µg (generic name: alprostadil), a prostaglandin E1 preparation; Limethason Intravenous Injection 2.5 mg (generic name: dexamethasone palmitate), a synthetic adrenocortical hormone; Pazucross® Injection 300 mg and 500 mg (generic name: pazufloxacin mesilate), a quinolone antibacterial agent for injections. The Company is taking this incident very seriously, and we offer our sincere apologies for causing concern and trouble to patients, health care professionals, and others affected by this incident.

The Company has consigned the manufacturing of the products that are the subject of this recall to a consolidated subsidiary, Mitsubishi Tanabe Pharma Factory Ltd. (Head Office: Chuo-ku, Osaka, President: Takashi Tanaka). The products are manufactured at Mitsubishi Tanabe Pharma Factory's Ashikaga Plant. Quality testing is conducted to determine if products are suitable for shipping, and it has been confirmed that, for certain lots of these products, some aspects of that testing were inadequate. Accordingly, the Company has decided to implement a voluntary recall of certain lots of these products.

The Company has used retention samples to conduct quality testing of these products and has confirmed that there are no problems with quality. In addition, we have not received any reports of health problems resulting from this incident.

In the future, we will investigate the causes of this incident and formulate corrective measures. Moreover, the entire group will continue working together to prevent a recurrence.

In regard to the influence of this incident on the company's results, in the event that there are any items that need to be disclosed, the Company will provide notice in a timely manner.